Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
Background
Pallavi Prasad
On the right TRACK? Rivaroxaban to prevent ...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?

kidney biopsy

Nefrópatia no diabética: El Resumen Visual

¿Hemos subestimado la frecuencia de la nefrópatía no diabética (NND) en pacientes diabeticos? Una cohorte basada en biopsias renales de 49,075 pacientes refuerza cuán heterogénea puede ser la NND y destaca las características clínicas más asociadas con la NND. ¿A quién debemos biopsiar? ¿Cuándo debemos sospecharla? ¿Cómo puede la histología cambiar el pronóstico?

Acompáñanos este martes en la discusión de #NephJC.

Nondiabetic Kidney Disease: The Visual Abstract

Have we been underestimating NDKD in patients with diabetes? A biopsy-based cohort of 49,075 patients reinforces just how heterogeneous kidney disease can be in DN and highlights the clinical features most strongly associated with NDKD. So, who should we biopsy? When should we suspect NDKD? And how can histology change prognosis?

Join us for this tuesday on the #NephJC discussion

¿Es eficaz la desmopresina para reducir el riesgo de sangrado tras una biopsia renal?

¿Cuál es la eficacia de la desmopresina tras la biopsia renal?
Prasad et al muestra una reducción significativa de sangrado. ¿Será el beneficio consistente según los subgrupos de acuerdo a la TFGe? Revisa el resumen visual creado por Divya Bajpai.